Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Current Leases (2021 - 2026)

Axsome Therapeutics' Current Leases history spans 6 years, with the latest figure at $628000.0 for Q1 2026.

  • On a quarterly basis, Current Leases fell 65.42% to $628000.0 in Q1 2026 year-over-year; TTM through Mar 2026 was $628000.0, a 65.42% decrease, with the full-year FY2025 number at $2.5 million, up 38.69% from a year prior.
  • Current Leases hit $628000.0 in Q1 2026 for Axsome Therapeutics, down from $2.5 million in the prior quarter.
  • Over the last five years, Current Leases for AXSM hit a ceiling of $2.5 million in Q4 2025 and a floor of $108000.0 in Q1 2023.
  • Historically, Current Leases has averaged $1.0 million across 5 years, with a median of $709120.0 in 2022.
  • Biggest five-year swings in Current Leases: plummeted 88.83% in 2023 and later skyrocketed 485.19% in 2024.
  • Tracing AXSM's Current Leases over 5 years: stood at $425000.0 in 2022, then surged by 198.12% to $1.3 million in 2023, then skyrocketed by 44.83% to $1.8 million in 2024, then skyrocketed by 38.69% to $2.5 million in 2025, then crashed by 75.32% to $628000.0 in 2026.
  • Business Quant data shows Current Leases for AXSM at $628000.0 in Q1 2026, $2.5 million in Q4 2025, and $2.5 million in Q3 2025.